Origins and Background
Selank and Semax are synthetic neuropeptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Both compounds were designed as stable, synthetic analogues of naturally occurring neuropeptides with enhanced CNS penetration and resistance to enzymatic degradation, properties that make them practical subjects for neurological research.
While these compounds have been approved and in clinical use in Russia and some Eastern European countries for specific neurological and anxiety-related indications, they remain investigational compounds in the United States and have not received FDA approval. The published literature on both compounds originates predominantly from Russian and Eastern European research institutions.
Selank: Structure and Mechanism
Selank (TP-7) is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, derived from the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg). Selank was designed with modifications to improve metabolic stability and CNS bioavailability compared to native tuftsin.
Research has identified multiple proposed mechanisms for Selank's observed anxiolytic effects. Studies published by Seredenin and colleagues at the Institute of Pharmacology characterized Selank as a modulator of GABAergic neurotransmission, specifically through allosteric enhancement of GABA-A receptor activity, a mechanism shared by benzodiazepine anxiolytics, though with a distinct binding site and reportedly different side effect profile in preclinical models.
Additional research has examined Selank's effects on serotonin metabolism. Studies in rodent models reported increased tryptophan hydroxylase activity and elevated serotonin levels in brain regions associated with anxiety regulation following Selank administration. The compound has also been studied for its effects on enkephalin degradation enzymes, with data suggesting it may increase the stability and availability of endogenous enkephalins.
Selank: Cognitive Research
Beyond anxiolytic activity, research has examined Selank's effects on cognitive function in rodent models of learning and memory. Studies using maze paradigms and passive avoidance models reported that Selank improved spatial memory acquisition and retention. Proposed mechanisms include enhancement of BDNF expression in hippocampal tissue and modulation of dopaminergic tone in prefrontal regions. These findings have positioned Selank as a subject of interest for researchers studying anxiety-cognition interactions and the neurochemistry of stress resilience.
Semax: Structure and Mechanism
Semax is a synthetic heptapeptide analogue of the ACTH(4-7) fragment, with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. The ACTH(4-7) sequence was identified as the neurologically active portion of adrenocorticotropic hormone, responsible for cognitive and adaptational effects independent of its adrenocortical actions. Semax extends this sequence with a Pro-Gly-Pro C-terminal addition that enhances metabolic stability in CNS tissue.
Semax's primary characterized mechanism at the molecular level involves upregulation of brain-derived neurotrophic factor (BDNF) expression in cerebral cortex and hippocampus. Multiple studies have reported 2–4 fold increases in BDNF mRNA expression in rodent brain tissue following Semax administration. BDNF is a key regulator of neuronal survival, synaptic plasticity, and the formation of long-term memory, making compounds that modulate its expression subjects of significant interest in neuroscience research.
Semax: Neuroprotection and Stroke Research
A substantial portion of Semax research has examined its effects in models of neurological injury, particularly ischemia. Studies in rodent stroke models (middle cerebral artery occlusion) demonstrated that Semax reduced infarct volume, attenuated edema formation, and improved neurological outcome scores when administered shortly after injury. These effects are proposed to involve both BDNF-mediated neuroprotection and anti-inflammatory modulation through suppression of pro-inflammatory cytokines in peri-ischemic tissue.
Semax has been registered in Russia for clinical use in stroke rehabilitation, a context in which its BDNF-upregulating and neuroprotective properties have been applied clinically, though the clinical trial data supporting this indication are predominantly from Russian-language literature and smaller studies by Western standards.
Comparative Research Considerations
Researchers studying these compounds should note that the published literature, while substantive, is predominantly derived from Eastern European institutions and may use methodological standards that differ from those of large Western clinical trials. The mechanistic characterization of both compounds is well-developed at the preclinical level, but large-scale randomized controlled trial data meeting FDA standards does not currently exist for either compound in Western-reviewed literature.
Selected References
- Zozulia AA, et al. (2008). Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova, 108(4):38–48.
- Volkova A, et al. (2016). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology, 7:31.
- Dolotov OV, et al. (2006). Semax, an Analog of ACTH(4–10) with Cognitive Effects, Regulates BDNF and trkB Expression in the Rat Hippocampus. Brain Research, 1117(1):54–60.
- Eremin KO, et al. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12):1493–500.